Methods: In protocol 9801, 401 pts with BM from any primary tumor were randomized to receive WBRT alone (30 Gy/10 fractions) or MGd, 5 mg/kg qd x 10 days, with WBRT. The subgroup of 251 pts with NSCLC is included in this analysis. In protocol 0211, 554 pts with BM from NSCLC were randomized to the same treatments. In both studies, eligibility included a KPS ≥ 70, no liver metastases, and ≤ 1 site of extracranial metastasis. In both studies, patients underwent a battery of neurocognitive tests measuring memory and executive function at baseline and all subsequent monthly follow-up visits. Progressions were defined as a confirmed decline from baseline of 1.5 standard deviations, corrected for age and educational background. Results: 805 pts received WBRT (N=403) or MGd+WBRT (N=402). Most pts had multiple BM (81%), extracranial metastases (47%) and presented with neurologic deficits (84%). Treatment arms were balanced for key prognostic factors. At baseline, 77% of all patients had some degree of neurocognitive deficit with 18% having one test result abnormal, 20% having two, 18% having three, 16% having four and 5% having all five test results abnormal. Memory was the most frequently impaired function (57%). Baseline neurocognitive impairments were balanced across treatment arms. Patients treated with MGd+WBRT were less likely during follow-up to show evidence of neurocognitive progression in memory function (HR=0.80, p=0.047), in executive function (HR=0.74, p=0.028) or in a combined score for all tests, (HR=0.78, p=0.02). Conclusions: Consistent with the delay in time to clinical neurologic progression seen in a previous pooled analysis, treatment with MGd+WBRT decreased progression in each function measured by standardized neurocognitive testing in the pooled dataset from 2 randomized phase III trials.
Surgery offers the best chance of cure for patients with NSCLC, but the 5-year survival rate is modest, and improvements are urgently required. Following striking results in favour of neo-adjuvant chemotherapy in 2 small trials, the current trial was designed to investigate whether, in patients with operable NSCLC of any stage, platinumbased chemotherapy given prior to surgery would improve outcomes. Methods: The primary endpoint was overall survival, and secondary endpoints were: quality of life, pathological staging, resectability rates, extent of surgery, and time to and site of relapse. The trial was designed to detect a 15% improvement in 3-year survival (from 40% to 55%) with neo-adjuvant chemotherapy (5% significance level, 90% power), which required 450 patients and 233 events (deaths). Patients were randomised to receive either surgery alone (S), or 3 cycles of platinum-based chemotherapy prior to surgery (CT-S), clinicians choosing (pre-randomisation) the chemotherapy from 6 standard regimens. Quality of Life was assessed by patients completing the SF-36 questionnaire at baseline (pre-randomisation), 6 and 12 months, and then annually to 5 years.
